• Users Online: 1143
  • Print this page
  • Email this page
 
ORIGINAL ARTICLE
Ahead of Print

Patient-reported outcomes from a phase IV study of aflibercept in patients with refractory retinal vein occlusions


1 Sydney Retina; Sydney Institute of Vision Science; University of Sydney, NSW, Australia
2 Sydney Retina; University of Sydney, NSW, Australia
3 Sydney Retina; Sydney Institute of Vision Science, NSW, Australia

Correspondence Address:
Andrew Chang,
Sydney Retina, Level 13, Park House 187 Macquarie Street, Sydney NSW, Australia 2000
Australia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjo.tjo_19_20

PURPOSE: To determine the patient-centered effectiveness of switching patients with persistent macular edema due to retinal vein occlusion (RVO) to aflibercept using the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25). MATERIALS AND METHODS: Prospective study of eyes with persistent cystoid macular edema due to RVO despite regular treatment with bevacizumab or ranibizumab switched to aflibercept. Three loading doses of intravitreal aflibercept were administered every 4 weeks and thereafter every 8 weeks until week 48. Vision-related quality of life (VRQoL) using NEI-VFQ-25 was measured at baseline, 24 weeks, and 48 weeks following the switch. Baseline scores were compared to week 24 and 48 using paired t-test. Relationship between best-corrected visual acuity (BCVA) in the study eye and the NEI-VFQ-25 composite and subscale scores was investigated. RESULTS: Eighteen patients with RVO were enrolled in the study with a mean age of 70.3 ± 8.6 years. The mean change in BCVA and central macular thickness (CMT) from baseline to 48 weeks was +20.6 ± 5.2 Early Treatment of Diabetic Retinopathy Score letters and −109.2 ± 82.8 μm, respectively. VRQoL improved significantly, with an increase of mean NEI-VFQ composite score of 11.5 ± 9.5; the corresponding improvements in near and distant activities were 13.3 ± 19.4 and 8.4 ± 10.4, respectively (P < 0.001 for both). Logistic regression analysis demonstrated that BCVA gain of >15 letters and CMT < 300 μm at the end of the study predicted a higher change in VFQ-25. CONCLUSION: Switching eyes with persistent macular edema due to RVO to aflibercept resulted in significant improvement in visual function and patient satisfaction.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Spooner K
    -  Fraser-Bell S
    -  Hong T
    -  Chang A
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed174    
    PDF Downloaded7    

Recommend this journal